Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00469612 · ClinicalTrials.gov registry record · NA

Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment

A NA study, sponsored by Ohio State University.

Terminated
Registry status
NA
Development phase
2
Enrollment target

NCT00469612 is a NA study that was terminated before completion, run by Ohio State University. The registered enrollment target is 2 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00469612, a NA study, was terminated before completion, sponsored by Ohio State University.

TERMINATED
Registry status
NA
Development phase
2 participants
Enrollment target

Study Summary

The purpose of the present study is to carry out a trial to evaluate the clinical efficacy of the NeuroVision Low Myopia Treatment. The specific questions to be answered are: 1. Is there an improvement in vision following the treatment without bringing about a change in the subject's prescription for glasses? 2. Can any treatment effect be seen at 6 months and 12 months after the termination of the treatment?

Interventions

  • DEVICE NeuroVision's NVC treatment for Low Myopia

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2007-06
Est. Completion 2009-12-01
Phase NA

Sponsor

Ohio State University

552 total trials

What the Registry Record Tells You About NCT00469612

The ClinicalTrials.gov registry entry for NCT00469612 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which NeuroVision's NVC treatment for Low Myopia is the first listed.

NCT00469612 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00469612 about?

NCT00469612 is a clinical study titled "Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment". The purpose of the present study is to carry out a trial to evaluate the clinical efficacy of the NeuroVision Low Myopia Treatment. The specific questions to be answered are: 1. Is there an improvement in vision following the treatment without bringing about a change in the subject's prescription ...

What is the current status of trial NCT00469612?

This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2007-06. Estimated completion is 2009-12-01.

What interventions are being tested in trial NCT00469612?

The interventions under investigation include: NeuroVision's NVC treatment for Low Myopia (DEVICE).

Who is sponsoring clinical trial NCT00469612?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.